Throughout the discussion, Norton offers a nuanced perspective grounded in a meticulous analysis of available research data and trends across multiple high-quality studies
Here are 3 trends from 2025 that every benefits leader should see: GLP-1-related HSA spending increased 5,610% year over year
After 28 days of use, discard the vial even if medication remains inside, because the rubber stopper exposure allows bacterial growth and oxidation
Tirzepatide treatment was administered at three final doses (5, 10, 15 mg per week), with treatment initiated at 2.5 mg and the dose escalated every 4 weeks
Key Research Characteristics: Extended half-life (~2030 hours vs ~1215 minutes for native IGF-1) due to reduced IGFBP binding Potent agonist at IGF-1R, studied for roles in cellular proliferation, differentiation, and survival signalling Investigated in models of muscle hypertrophy, neuroprotection, and metabolic regulation 83 amino acid analogue
Evaluate response and further increase the total weekly dose in 2.5/mg increments, as needed
